Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fobrepodacin - Spero Therapeutics

Next Previous
Drug Profile

Fobrepodacin - Spero Therapeutics

Alternative Names: pVXc-486; SPR-720; VXc-100/VXc486; VXC-486 phosphate

Latest Information Update: 27 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Spero Therapeutics
  • Class Antibacterials; Antituberculars; Benzimidazoles; Fluorinated hydrocarbons; Furans; Phosphates; Pyrimidines; Urea compounds
  • Mechanism of Action DNA gyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nontuberculous mycobacterium infections
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Nontuberculous mycobacterium infections
  • No development reported Tuberculosis

Most Recent Events

  • 02 Dec 2024 Spero Therapeutics completes a phase-II trial in Nontuberculous mycobacterium infections (Treatment naive) in USA (PO, Capsule), , (NCT05496374)
  • 31 Oct 2024 Suspended - Phase-II for Nontuberculous mycobacterium infections (In the elderly, Treatment-naive, In adults) in USA (PO)
  • 31 Oct 2024 Suspended - Phase-II for Nontuberculous mycobacterium infections (Treatment-naive) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top